

Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Irtegun, S;Wood, R;Lackovic, K;Schweiggert, J;Ramdzan, YM;Huang, DCS;Mulhern, TD;Hatters, DM

Title:

A biosensor of Src family kinase conformation by exposable tetracysteine useful for cell-based screening

Date:

2014-07-18

Citation:

Irtegun, S., Wood, R., Lackovic, K., Schweiggert, J., Ramdzan, Y. M., Huang, D. C. S., Mulhern, T. D. & Hatters, D. M. (2014). A biosensor of Src family kinase conformation by exposable tetracysteine useful for cell-based screening. *ACS Chemical Biology*, 9 (7), pp.1426-1431. <https://doi.org/10.1021/cb500242q>.

Persistent Link:

<https://hdl.handle.net/11343/57503>

**A biosensor of Src family kinase conformation by exposable tetracysteine useful for cell-based screening.**

Sevgi Irtegun<sup>1,2</sup>, Rebecca Wood<sup>1,2</sup>, Kurt Lackovic<sup>3,4</sup>, Jörg Schweiggert<sup>1</sup>, Yasmin M. Ramdzan<sup>1</sup>, David C.S. Huang<sup>3,4</sup>, Terrence D. Mulhern<sup>1\*</sup> & Danny M. Hatters<sup>1\*</sup>

<sup>1</sup>Department of Biochemistry and Molecular Biology; and Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, VIC 3010.

<sup>2</sup>Equally contributed to the work.

<sup>3</sup>Walter and Eliza Hall Institute of Medical Research, VIC 3010

<sup>4</sup>Department of Medical Biology, University of Melbourne, VIC 3010

\*Correspondence should be addressed to D.M.H. ([dhatters@unimelb.edu.au](mailto:dhatters@unimelb.edu.au)) or

T.D.M. ([tmulhern@unimelb.edu.au](mailto:tmulhern@unimelb.edu.au)) . Ph: +61 38344 2530.

## **ABSTRACT**

**We developed a new approach to distinguish distinct protein conformations in live cells. The method, exposable tetracysteine (XTC), involved placing an engineered tetracysteine motif into a target protein that has conditional access to biarsenical dye binding by conformational state. XTC was used to distinguish open and closed regulatory conformations of Src family kinases. Substituting just four residues with cysteines in the conserved SH2 domain of three Src-family kinases (c-Src, Lck, Lyn) enabled open and closed conformations to be monitored based on binding differences to biarsenical dyes FAsH or ReAsH. Fusion of the kinases with a fluorescent protein tracked the kinase presence, and the XTC approach enabled simultaneous assessment of regulatory state. The c-Src XTC biosensor was applied in a boutique screen of kinase inhibitors, which revealed six compounds to induce conformational closure. The XTC approach demonstrates new potential for assays targeting conformational changes in key proteins in disease and biology.**

Our knowledge of the mechanical operation of proteins in live cells has remained difficult to determine due to a dearth of methods. Fluorescence resonance energy transfer (FRET) has been a major method, particularly in the development of metabolite biosensors (*1*), but is not suitable for all systems and contexts. For assessing conformational changes in proteins, FRET typically requires the expression of two fluorescent protein fusions to a target protein, which may be difficult to accommodate without major impedance to protein function. The emergence of chemical biology avenues offers much potential to greatly expand the repertoire of methods to address these challenges. One example is the capacity of a tetracysteine

(TC) motif, CCXXCC, to bind biarsenical fluorophores FAsH and ReAsH with high affinity and specificity in live cells (2). The binary nature of the system and small size of the dyes have enabled innovative applications for investigating protein self-association, folding and oligomerization (3-5).

Here, we describe a new approach for tracking alternate conformations of Src family kinases (SFKs) using an exposable tetracysteine (XTC) sequence with conformation-specific biarsenical dye reactivity. SFKs modulate signaling pathways that drive cell growth, differentiation, proliferation, apoptosis, adhesion and migration. They are overactive in a wide variety of human cancers, making them attractive therapeutic targets (6). SFKs have “open” active and “closed” inactive conformations that are well understood at an atomic level (7, 8) (Fig 1a). The activity of c-Src in terms of the local balance of the upstream kinase and upstream phosphatase activities can now be measured spatially in live cells using FRET reporters of the phosphorylation status of a c-Src substrate (9); however, its regulatory state remains more challenging to monitor. Prior work established an approach involving microinjection of an extrinsic probe that selectively binds the SFK SH3 domain in the open conformation (10). This method is highly sensitive, but not amenable for high throughput assays and does not discriminate between different SFK members (11).

By introducing mutations R159C, E160C, R163C and L164C in the SH2 domain of human c-Src, we created an exposable TC construct (c-Src<sup>XTC</sup>) predicted to be solvent exposed only in the open state and have a geometry permissive to FAsH and ReAsH binding (7, 8, 12) (Fig 1a). To test whether c-Src<sup>XTC</sup> bound biarsenical dyes in a conformation-specific manner, the construct was superimposed onto “open” active or “closed” inactive mutant backgrounds and transiently expressed in AD293 cells under a high yielding CMV promoter. c-Src<sup>XTC</sup><sub>open</sub> and c-Src<sup>XTC</sup><sub>closed</sub> have additional

mutations (Open: Y530F and closed: Q531E, P532E, G533I) that alter the affinity of the C-tail to the SH2 domain, an interaction which stabilizes the closed form (13). To provide an independent measure of c-Src expression and localization, the monomeric GFP variant Emerald was fused to the C-terminus, via a linker sequence previously validated to preserve the major functionality of c-Src (14) (Fig 1b).

c-Src<sup>XTC</sup>, c-Src<sup>XTC<sub>open</sub></sup> and c-Src<sup>XTC<sub>closed</sub></sup> were assessed for ReAsH red-fluorescent biarsenical dye reactivity in live cells, relative to a negative control (c-Src<sup>NTC</sup>) with no TC tag, and a positive control (c-Src<sup>CTC</sup>) that had the TC tag appended in a highly accessible position on the C-terminal of Emerald (Fig 1b, Supplementary Table 1). c-Src<sup>XTC<sub>open</sub></sup> had approximately 80% of the fluorescent yield of the positive control, c-Src<sup>XTC<sub>closed</sub></sup> was similar to the negative control and c-Src<sup>XTC</sup> was intermediate between open and closed variants (Fig 1c). These data indicate that c-Src<sup>XTC</sup> reports on c-Src conformation with good differential in the signal between the open and closed states.

For a more quantitative and high throughput assessment using flow cytometry, we adapted the reporter color scheme for standard flow cytometry filter sets and laser combinations (to which ReAsH is not well-suited). The Emerald moiety was replaced with the monomeric Cerulean fluorescent protein and the binding of the TC tag was examined with the green-fluorescent biarsenical dye FAsH. Cytograms plotting Pacific-Blue (for Cerulean) versus FITC (for FAsH) confirmed conformation-dependent differences in FAsH reactivity, similar to the patterns observed by microscopy with the Emerald/ReAsH combination (Fig 2a). A simple quantitative measure of “closure” was found by gating for high FAsH fluorescence and calculating the percent of cells within this gate (Fig 2a, 2b). The majority of cells expressing c-Src<sup>XTC<sub>open</sub></sup> were high-FAsH-reactive, whereas the majority of those expressing c-Src<sup>XTC<sub>closed</sub></sup> were low-FAsH-reactive (Fig 2a, 2b).

To make the reporter more generally useful as a tool for the study of SFKs, we examined whether other members of the family could be converted into biosensors of open and closed conformations using the same strategy. The exposable TC motif was introduced at the equivalent SH2 locations of Lyn and Lck and the biosensors were superimposed onto open and closed mutant backgrounds. The Lck and Lyn sensors also exhibited conformation-sensitive FAsH reactivities (Fig 2b). All c-Src<sup>XTC</sup>, Lck<sup>XTC</sup> and Lyn<sup>XTC</sup> had FAsH reactivities significantly higher than those of their respective closed variants (Fig 2b). Because SFKs are largely inactive under basal conditions (15), our results raise the possibility that XTC mutations shift the conformational equilibrium towards the open state. Examination of the ability of the SFKs to phosphorylate substrate STAT3 found that the XTC mutations led to an increased basal kinase activity (Fig 3a). The SH2 domain of c-Src<sup>XTC</sup> remained folded (Fig 3b) but had a three-fold decreased binding affinity to phosphotyrosine (Fig 3c), which accounts for the destabilization of the closed state. In addition, we cannot exclude the possibility that the mutated residues abrogate direct or water-mediated electrostatic interactions with the C-lobe of the kinase domain of Src. This may limit the application of the biosensors to physiological problems. However, the shift towards the open state provides the dynamic range required to enable screening for compounds that induce closure.

Therefore, we next assessed whether the XTC sensors can be used to assay drugs for their effect on c-Src conformation. To our knowledge, there are no high-throughput drug screening platforms that assess changes in the regulatory state of SFKs in live cells, which have the potential to be used to identify inhibitors with novel mechanisms of action. To test for this capability, the c-Src<sup>XTC</sup> biosensor was screened against a library of 72 kinase inhibitors that had no inherent fluorescence based on a

pre-screen on untransfected cells. After a 2 hour treatment with the drugs at 5  $\mu$ M, COS-1 cells were labeled with FIAsh and analyzed by flow cytometry. The screen identified drugs that appeared to induce c-Src closure as well as those that appeared to open c-Src; however, the majority had no statistically significant effect on c-Src<sup>XTC</sup> conformation, including compounds known to inhibit c-Src (Supplementary Table 2). This is unsurprising since the majority of kinase inhibitors target the ATP binding site in the active DFG-in conformation (as opposed to the catalytically inactive DFG-out conformation) (16), and would therefore not be expected to induce c-Src closure. For example, the clinical c-Src and BCR-Abl inhibitor bosutinib binds c-Src in the DFG-in conformation (17) and produced no significant change in FIAsh binding in the drug screen ( $p=0.64$ ; Supplementary Table 2). By assaying conformation rather than activity, the biosensor has the potential to identify inhibitors with novel mechanisms of action, and potentially how changes in the cellular signaling landscape impact on Src conformation through indirect pathways. Six compounds that increased c-Src closure were identified: PP1, PP2, tozasertib, CYC116, vandetanib and N2-[4-(Aminomethyl)phenyl]-5-fluoro-N4-phenylpyrimidine-2,4-diamine. Vandetanib targets EGFR and VEGFR (18); however, it has been shown to bind and inhibit c-Src (19). Tozasertib and CYC-116 target Aurora kinases (20, 21) and are reported to inhibit c-Src (22). N2-[4-(Aminomethyl)phenyl]-5-fluoro-N4-phenylpyrimidine-2,4-diamine is a pan kinase inhibitor; however, to our knowledge there is no available data specific to c-Src. PP1 and PP2 are gold standard c-Src inhibitors, with  $IC_{50}$  values of 50 nM and 100 nM, respectively in *in vitro* kinase assays (23).

We further validated PP1 and PP2 by concentration-response curves to calculate the half maximal effective concentration ( $EC_{50}$ ) for c-Src<sup>XTC</sup> conformational shift (Fig 4). Both PP1 and PP2  $EC_{50}$  values were estimated to be in the low micromolar range.

These values agree with other cell-based dose response data for PP2 (24); however, they are over two orders of magnitude greater than the *in vitro* IC<sub>50</sub> values. These results demonstrate limitations of *in vitro* data for biological problems and highlight the importance of cell-based assays in drug development.

Notably, no drugs induced complete closure of c-Src<sup>XTC</sup>. Both PP1 and PP2 reduced percent of high FAsH cells from over 80% to just under 70% (Fig 4), whereas the closed mutant had approximately 30% high FAsH (Fig 2b). The drugs are likely to alter the equilibrium between open and closed conformations; how this occurs remains to be determined. One possibility is that drug-induced changes in the active site conformation further toggle the open and closed states. Another consideration is that the high expression level of the SFKs in our assays may lead to hyperphosphorylation of the activation loop, which conceivably influences the potency of the drugs for conformational change.

In summary, we have developed a novel genetically encoded biosensor to study conformation of three SFKs: c-Src, Lck and Lyn with just 4 point mutations. Thus the XTC biosensor strategy provides a new capability to study modulation of SFK conformation in living cells and is in principle adaptable to other proteins, especially those to which detailed structural knowledge is available for modeling.

## FIGURE LEGENDS

### **Figure 1. Designing tetracysteine exposure to indicate c-Src conformation. a)**

The location of cysteine mutations in the SH2 domain of the c-Src<sup>XTC</sup> sensor are modeled on the crystal structures of open (1Y57) and closed (2SRC) c-Src with

ReAsH predicted to selectively bind the open conformation. **b)** Three basic variants

were used in this study. c-Src<sup>XTC</sup> (exposable TC) binds biarsenical dyes (FAsH or ReAsH) only in the open conformation. c-Src<sup>CTC</sup> (constitutive TC) binds biarsenical dyes regardless of conformation due to a tetracysteine tag at the C-terminus of the fluorescent protein fusion. c-Src<sup>NTC</sup> (no TC) lacks a tetracysteine tag. **c)** Confocal micrographs of AD293 cells expressing c-Src<sup>XTC</sup> superimposed onto open or closed mutant backgrounds. All variants are fused to Emerald fluorescent protein.

**Figure 2. The exposable TC sensor is adaptable to multiple SFKs** **a)** Gating strategy for flow cytometry analysis showing FAsH-labeled AD293 cells expressing Cerulean-fused c-Src<sup>XTC<sub>open</sub></sup> (blue) or c-Src<sup>XTC<sub>closed</sub></sup> (red). Cells were gated first for high expression then for high or low FAsH. The percent of high expressers that are high FAsH reactive was used for sample analysis. **b)** c-Src<sup>XTC</sup>, Lck<sup>XTC</sup> and Lyn<sup>XTC</sup> biosensors successfully distinguish open and closed mutant backgrounds using flow cytometry. Shown are means  $\pm$  S.E., n=3. \*\*, p<0.01; \*\*\*, p<0.001; one tailed t-test.

**Figure 3. Effect of exposable TC mutations on structure and activity of SFKs.** **a)** Kinase activity of SFKs as indicated by levels of phosphorylated substrate STAT3 (pSTAT3), compared to total STAT3. **b)** Circular dichroism spectra of the purified no TC (NTC) and TC-containing (XTC) SH2 domains indicate the tetracysteine-containing domain folds properly. **c)** Binding curves for the interaction of the SH2 domains with the high affinity pYEEI peptide ligand. The fluorescence anisotropy of FITC-labeled peptide was measured versus protein concentration. Error bars on data points indicate S.E. from 5 repeated-measures. The TC mutation caused a decrease in affinity of the SH2 for the peptide ( $K_d$  from  $0.43 \pm 0.07 \mu\text{M}$  to  $1.50 \pm 0.21 \mu\text{M}$ ; errors indicate S.E. of the estimate from the fit).

**Figure 4. c-Src<sup>XTC</sup> detects inhibitor-induced conformational closure.**

Concentration response curves are shown for two hits from the drug screen, SFK

inhibitors PP1 and PP2. Error bars show means  $\pm$  S.E. (n=8), reported error in EC<sub>50</sub> values are S.E. of the estimate from the fit.

## **METHODS**

**DNA constructs.** c-Src (NP\_005408), Lyn (NP\_002341) and Lck (NP\_005347) cDNA appended C-terminally with linkers encoding amino acids GSGSDPPVAT, GSGSGSDPPVAT, AGSGSGSDPPVAT respectively, as well as XTC variants thereof (R159C, E160C, R163C, L164C), (K137C, D138C, R141C, Q142C) and (K135C, D136C, R139C, Q140C) respectively, were commercially synthesized using human-optimized codons and cloned into pT-Rex (Life Technologies). Cerulean, Emerald (25) and the C-terminal amino acid sequence CCPGCC (for c-Src<sup>CTC</sup>) were introduced via PCR-mediated cloning. Open (Src: Y530F; Lyn: Y508F; Lck: Y505F) and closed (Src: Q531E, P532E, G533I; Lyn: Q509E, Q510E, Q511I; Lck: Q506E, P507E, Q508I) mutations were introduced using QuikChange mutagenesis (Stratagene).

**Cloning & expression of the SH2 domain.** SH2 sequences (residues 145–249) were cloned via PCR from c-Src<sup>XTC</sup> and c-Src<sup>NTC</sup> into pET21(d). A 6×His-tag was added to the N-terminus of the SH2<sup>XTC</sup> by PCR-mediated cloning. Proteins were expressed in BL21(DE3) *E. coli* and purified by phosphotyrosine affinity chromatography (SH2<sup>NTC</sup>) or Ni<sup>2+</sup>-affinity chromatography (SH2<sup>XTC</sup>) to >95% purity. Correct masses were confirmed using a 6510 Q-TOF LC/MS (Agilent Technologies).

**Mammalian cell culture.** AD293 and COS-1 cells were maintained in DMEM supplemented with 10% FCS, 1 mM glutamine, 100 U/mL penicillin and 100 U/mL streptomycin in a humidified incubator with 5% CO<sub>2</sub>.

**ReAsH staining and imaging.**  $8 \times 10^4$  AD293 cells were plated into 8-well  $\mu$ -slides (Ibidi) pre-coated with 0.01% (w/v) poly-L-lysine and transfected the following day with 0.5  $\mu$ g of DNA using Lipofectamine 2000. After 24 hours, cells were labelled for 30 min with 10  $\mu$ M 1,2-ethanedithiol (EDT), 2.5  $\mu$ M ReAsH (Life Technologies) in HBSS then washed for 15 min in 250  $\mu$ M 2,3-dimercaptopropanol (BAL) in HBSS. Cells were fixed with 3.2% (w/v) paraformaldehyde for 15 min at room temperature then imaged by a TCS SP2 confocal microscope (Leica). Emerald and ReAsH fluorescence were collected using 458 nm and 543 nm excitation lasers and emission wavelengths of 510–530 nm and 580–640 nm, respectively.

**Western Blotting.** Western blotting was performed as described previously (13). Blots were matched for total STAT3 then equivalent blots were probed for phospho-STAT3 or GFP (for SFK levels). Antibodies used were 1:10,000 anti-GFP from Life Technologies, 1:1,000 anti-STAT3 from BD Biosciences and 1:1,000 anti-phospho STAT3 from Cell Signalling.

**Flow cytometry & analysis.** Preparation of cells for flow cytometry, FAsH labelling, and the cytometer configuration were as described previously (26). Cerulean and FAsH fluorescence were collected using the Pacific blue (405 nm laser, 450/50 nm bandpass filter) and FITC (488 nm laser, 530/30 nm bandpass filter) channels, respectively.

Data were analyzed using FlowJo (TreeStar, Inc.) by gating for high expression (Cerulean fluorescence above 500 AFU) then for high or low FAsH reactivity. The high FAsH gate was defined as a diagonal line in a logarithmic FAsH to Cerulean cytogram that was adjusted by translation so as to contain 80% cells expressing c-Src<sup>XTC</sup>. The percent of high expressing cells with high FAsH was calculated.

For drug screening,  $6.6 \times 10^4$  COS-1 cells were transfected in solution with 0.32  $\mu\text{g}$  c-Src<sup>XTC</sup>-Cerulean DNA using 0.4  $\mu\text{L}$  Lipofectamine 2000 and plated in 96-well tissue culture plates. The following day, cells were treated for 2 h with 5  $\mu\text{M}$  drug or DMSO vehicle in HBSS. PP1 and PP2 were from Sigma and all other drug screen compounds were supplied by the Walter and Eliza Hall HTS group. FIAsh staining was performed as described previously (3). 100  $\mu\text{L}$  cell suspension was analyzed using an LSRFortessa flow cytometer equipped with a high throughput sampler at 2.5  $\mu\text{L}/\text{sec}$ . Three independent experiments were conducted with randomised compound locations. Concentration response curves were performed under the same conditions with 8 replicates. Half-maximal effective concentrations ( $\text{EC}_{50}$  values) were estimated by fitting to a four-parameter sigmoidal equation using Sigmaplot 12 (Systat).

**Statistics.** For the drug screen, percent high FIAsh values were normalised to plate means and standard deviations using the z-score method (27). Z-scores across replicates were compared to DMSO vehicle controls and hits were identified via a two-tailed t-test with respect to the DMSO control, with a cut-off of  $p < 0.05$ .

**Circular dichroism spectroscopy.** Circular dichroism (CD) spectra of 0.2 mg/mL protein were measured in a 1 mm pathlength cuvette in 10 mM phosphate pH 7, 1 mM DTT at 20 °C using a model 410 SF CD spectrometer (Aviv) at 100 nm/min in continuous scanning mode with a 0.5 nm data-pitch. Final spectra were averages of 3 scans with buffer subtraction.

**SH2 Binding assay.** The phosphotyrosyl peptide corresponded to residues 321–331 of the hamster polyomavirus middle T antigen (NP\_056731) phosphorylated at Tyr342 (pY) was synthesized commercially (GL Biochem) with FITC attached to the N-terminus via aminocaproic acid (Acp) (FITC-Acp-EPQpYEEIPIYL). Dilution

titrations were measured in 50 mM Tris pH 7.4, 150 mM NaCl, 12.5 mM imidazole, 1 mM TCEP using a Cary Eclipse fluorescence spectrophotometer with automated polarizers (Agilent Technologies). Equilibrium dissociation constant ( $K_d$ ) values were calculated as described previously (28).

*Information Available:* Supplementary Tables 1 and 2 is made free of charge *via* the Internet at <http://pubs.acs.org>

## **ACKNOWLEDGEMENTS**

The work was funded in part by grants to D.M.H. and T.D.M. from the Australian National Health and Medical Research Council and the Australian Research Council. D.M.H. was a Grimwade Fellow, supported by the Miegunyah Trust and currently an ARC Future Fellow. The Huang lab is supported by the Australian National Health and Medical Research Council (Program Grant 1016701; Independent Research Institutes Infrastructure Support Scheme grant 361646), the Leukemia and Lymphoma Society (SCOR grants) and a Victorian State Government Operational Infrastructure Support (OIS) Grant.

## **AUTHOR CONTRIBUTIONS**




D.M.H. and T.D.M. conceived the sensor design, oversaw the project, its implementation and preparation of the manuscript. R.W. designed and performed experiments, interpreted data and co-wrote the manuscript. S.I. performed experiments, helped analyse data and assisted in drafting the manuscript. J.S. and Y.R. performed experiments, helped interpret data and contributed to the writing of



the manuscript. K.L. and D.C.S.H. contributed to the design of the drug screen and oversaw its implementation.




## REFERENCES



1. Bermejo, C., Ewald, J. C., Lanquar, V., Jones, A. M. & Frommer, W. B. . (2011) *In vivo* biochemistry: quantifying ion and metabolite levels in individual cells or cultures of yeast, *Biochem. J.* 438, 1–10.
2. Griffin, B. A., Adams, S. R., and Tsien, R. Y. (1998) Specific Covalent Labeling of Recombinant Protein Molecules Inside Live Cells, *Science* 281, 269–272.
3. Ramdzan, Y. M., Nisbet, R. M., Miller, J., Finkbeiner, S., Hill, A. F., and Hatters, D. M. (2010) Conformation sensors that distinguish monomeric proteins from oligomers in live cells, *Chem. Biol.* 17, 371–379.
4. Luedtke, N. W., Dexter, R. J., Fried, D. B., and Schepartz, A. (2007) Surveying Polypeptide and Protein Domain Conformation and Association with FAsH and ReAsH, *Nat. Chem. Biol.* 3, 779–784.
5. Ignatova, Z., and Gierasch, L. M. (2004) Monitoring Protein Stability and Aggregation *in vivo* by Real-time Fluorescent Labeling, *Proc. Natl. Acad. Sci. USA* 101, 523–528.
6. Playford, M. P., and Schaller, M. D. (2004) The interplay between Src and integrins in normal and tumor biology, *Oncogene* 23, 7928–7946.
7. Cowan-Jacob, S. W., Fendrich, G., Manley, P. W., Jahnke, W., Fabbro, D., Liebetanz, J., and Meyer, T. (2005) The Crystal Structure of a c-Src Complex in an Active Conformation Suggests Possible Steps in c-Src Activation, *Structure* 13, 861–871.
8. Xu, W., Harrison, S., and Eck, M. (1997) Three-dimensional structure of the tyrosine kinase c-Src, *Nature* 385, 595–602.
9. Wang, Y., Botvinick, E., Zhao, Y., Berns, M., Usami, S., Tsien, R., and Chien, S. (2005) Visualizing the mechanical activation of Src, *Nature* 434, 1040–1045.
10. Gulyani, A., Vitriol, E., Allen, R., Wu, J., Gremyachinskiy, D., Lewis, S., Dewar, B., Graves, L. M., Kay, B. K., and Kuhlman, B. (2011) A biosensor generated via high-throughput screening quantifies cell edge Src dynamics, *Nat. Chem. Biol.* 7, 437–444.
11. Karatan, E., Merguerian, M., Han, Z., Scholle, M. D., Koide, S., and Kay, B. K. (2004) Molecular Recognition Properties of FN3 Monobodies that Bind the Src SH3 Domain, *Chem. Biol.* 11, 835–844.
12. Adams, S. R., Campbell, R. E., Gross, L. A., Martin, B. R., Walkup, G. K., Yao, Y., Llopis, J., and Tsien, R. Y. (2002) New Biarsenical Ligands and Tetracysteine Motifs for Protein Labeling *In vitro* and *In vivo*: Synthesis and Biological Applications, *J. Am. Chem. Soc.* 124, 6063–6076.
13. Irtegun, S., Wood, R. J., Ormsby, A. R., Mulhern, T. D., and Hatters, D. M. (2013) Tyrosine 416 Is Phosphorylated in the Closed, Repressed Conformation of c-Src, *PLoS One* 8, e71035.
14. Sandilands, E., Cans, C., Fincham, V. J., Brunton, V. G., Mellor, H., Prendergast, G. C., Norman, J. C., Superti-Furga, G., and Frame, M. C. (2004)

- RhoB and Actin Polymerization Coordinate Src Activation with Endosome-Mediated Delivery to the Membrane, *Dev. Cell* 7, 855–869.
15. Cooper, J. A., Gould, K. L., Cartwright, C. A., and Hunter, T. (1986) Tyr527 is phosphorylated in pp60c-src: implications for regulation, *Science* 231, 1431–1434.
  16. Yi, L., and Gray, N. S. (2006) Rational design of inhibitors that bind to inactive kinase conformations, *Nat. Chem. Biol.* 2, 358–364.
  17. Levinson, N. M., and Boxer, S. G. (2013) A conserved water-mediated hydrogen bond network defines bosutinib's kinase selectivity, *Nat. Chem. Biol.* 10, 127–132
  18. Brave, S. R., Odedra, R., James, N. H., Smith, N. R., Marshall, G. B., Acheson, K. L., Baker, D., Howard, Z., Jackson, L., and Ratcliffe, K. (2011) Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer, *Int. J. Oncol.* 39, 271–278.
  19. Jia, H.-Y., Wu, J.-X., Zhu, X.-F., Chen, J.-M., Yang, S.-P., Yan, H.-J., Tan, L., Zeng, Y.-X., and Huang, W. (2009) ZD6474 inhibits Src kinase leading to apoptosis of imatinib-resistant K562 cells, *Leuk. Res.* 33, 1512–1519.
  20. Harrington, E. A., Bebbington, D., Moore, J., Rasmussen, R. K., Ajose-Adeogun, A. O., Nakayama, T., Graham, J. A., Demur, C., Hercend, T., Diu-Hercend, A., Su, M., Golec, J. M., and Miller, K. M. (2004) VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo, *Nat. Med.* 10, 262–267.
  21. Wang, S., Midgley, C. A., Scaërou, F., Grabarek, J. B., Griffiths, G., Jackson, W., Kontopidis, G., McClue, S. J., McInnes, C., and Meades, C. (2010) Discovery of N-phenyl-4-(thiazol-5-yl) pyrimidin-2-amine aurora kinase inhibitors, *J. Med. Chem.* 53, 4367–4378.
  22. Bain, J., Plater, L., Elliott, M., Shpiro, N., Hastie, C., Mclauchlan, H., Klevernic, I., Arthur, J., Alessi, D., and Cohen, P. (2007) The selectivity of protein kinase inhibitors: a further update, *Biochem. J* 408, 297–315.
  23. Karni, R., Mizrachi, S., Reiss-Sklan, E., Gazit, A., Livnah, O., and Levitzki, A. (2003) The pp60(c-Src) inhibitor PP1 is non-competitive against ATP, *FEBS Lett.* 537, 47–52.
  24. Han, X., Yamanouchi, G., Mori, T., Kang, J.-H., Niidome, T., and Katayama, Y. (2009) Monitoring protein kinase activity in cell lysates using a high-density peptide microarray, *J. Biomol. Screen.* 14, 256–262.
  25. Olshina, M. A., Angley, L. M., Ramdzan, Y. M., Tang, J., Bailey, M. F., Hill, A. F., and Hatters, D. M. (2010) Tracking mutant huntingtin aggregation kinetics in cells reveals three major populations that include an invariant oligomer pool, *J. Biol. Chem.* 285, 21807–21816.
  26. Ramdzan, Y. M., Polling, S., Chia, C. P., Ng, I. H., Ormsby, A. R., Croft, N. P., Purcell, A. W., Bogoyevitch, M. A., Ng, D. C., Gleeson, P. A., and Hatters, D. M. (2012) Tracking protein aggregation and mislocalization in cells with flow cytometry, *Nat. Methods* 9, 467–470.
  27. Brideau, C., Gunter, B., Pikounis, B., and Liaw, A. (2003) Improved Statistical Methods for Hit Selection in High-Throughput Screening, *J. Biomol. Screen.* 8, 634–647.
  28. Mills, R. D., Trewhella, J., Qiu, T. W., Welte, T., Ryan, T. M., Hanley, T., Knott, R. B., Lithgow, T., and Mulhern, T. D. (2009) Domain organization of the monomeric form of the Tom70 mitochondrial import receptor, *J. Mol. Biol.* 388, 1043–1058.









**A biosensor of Src family kinase conformation by exposable tetracysteine useful for cell-based screening.**

Sevgi Irtegun<sup>1,2</sup>, Rebecca Wood<sup>1,2</sup>, Kurt Lackovic<sup>3,4</sup>, Jörg Schweiggert<sup>1</sup>, Yasmin M. Ramdzan<sup>1</sup>, David C.S. Huang<sup>3,4</sup>, Terrence D. Mulhern<sup>1\*</sup> & Danny M. Hatters<sup>1\*</sup>

<sup>1</sup>Department of Biochemistry and Molecular Biology; and Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, VIC 3010.

<sup>2</sup>Equally contributed to the work.

<sup>3</sup>Walter and Eliza Hall Institute of Medical Research, VIC 3010

<sup>4</sup>Department of Medical Biology, University of Melbourne, VIC 3010

\*Correspondence should be addressed to D.M.H. ([dhatters@unimelb.edu.au](mailto:dhatters@unimelb.edu.au)) or T.D.M. ([tmulhern@unimelb.edu.au](mailto:tmulhern@unimelb.edu.au)) . Ph: +61 38344 2530.

## SUPPLEMENTARY TABLES

**Supplementary Table 1: Amino acid sequences of the basic sensor constructs.**

<p><b>c-Src<sup>xtc</sup>- Cerulean</b></p> <ul style="list-style-type: none"> <li>• Linker in gray</li> <li>• Cerulean in cyan</li> <li>• TC in orange</li> </ul>	<p>MGSNKS PKDASQRRRSLEPAENVHGAGGGAFPASQTSPKSPASADGHRGPSAAF          APAAAEPKLFGGFNSSDVTSPQRAGPLAGGVTTFFVALYDYESRTETDLSFKKGE          RLQIVNNTEGDWLWLAHSLSTGQTGYIPSNYVAPSDSIQAEWYFGKITR<b>CCSECC</b>          LLNAENPRGTFLVRESETTKGAYCLSVSDFDNAKGLNVKHYKIRKLDSSGGFYITS          RTQFNLSLQQLVAYYSKHADGLCHRLTTVCPTSKPQTQGLAKDAWEIPRESLRLEV          KLGQGC FGEVWMGTWNGTTRVAIKTLKPGTMSPEAFLQEAQVMKKLRHEKLVQ          LYAVVSEPIYIVTEYMSKGSLLDFLKGETGKYLRLPQLVDMAAQIASGMAYVER          MNYVHRDLRAANILVGENLVCKVADFLARLIEDNEYTARQGAKFPIKWTAPEA          ALYGRFTIKSDVWSFGILLTELTTKGRVPYPMVNREVLDQVERGYRMPCEPCP          ESLHDLMCQCWRKEPEERPTFEYLQAFLEDYFTSTEPQYQGENLGS GSDPPVAT  <b>GSLVSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLT LKFICTTGK</b>  <b>LPVPWPTLVTTLTWGVQCFARYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNY</b>  <b>KTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNAISDNVYITADKQKNGIK</b>  <b>ANFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSKLSKDPNEKRDH</b>  <b>MVLEFVTAAGITLGMDELYK</b></p>
<p><b>c-Src<sup>ctc</sup>- Emerald</b></p> <ul style="list-style-type: none"> <li>• Linker in gray</li> <li>• Emerald in green</li> <li>• TC in orange</li> </ul>	<p>MGSNKS PKDASQRRRSLEPAENVHGAGGGAFPASQTSPKSPASADGHRGPSAAF          APAAAEPKLFGGFNSSDVTSPQRAGPLAGGVTTFFVALYDYESRTETDLSFKKGE          RLQIVNNTEGDWLWLAHSLSTGQTGYIPSNYVAPSDSIQAEWYFGKITRRESERLL          LNAENPRGTFLVRESETTKGAYCLSVSDFDNAKGLNVKHYKIRKLDSSGGFYITSR          TQFNLSLQQLVAYYSKHADGLCHRLTTVCPTSKPQTQGLAKDAWEIPRESLRLEVK          LGQGC FGEVWMGTWNGTTRVAIKTLKPGTMSPEAFLQEAQVMKKLRHEKLVQL          YAVVSEPIYIVTEYMSKGSLLDFLKGETGKYLRLPQLVDMAAQIASGMAYVER          MNYVHRDLRAANILVGENLVCKVADFLARLIEDNEYTARQGAKFPIKWTAPEA          ALYGRFTIKSDVWSFGILLTELTTKGRVPYPMVNREVLDQVERGYRMPCEPCP          ESLHDLMCQCWRKEPEERPTFEYLQAFLEDYFTSTEPQYQGENLGS GSDPPVAT  <b>GSLVSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLT LKFICTTGK</b>  <b>LPVPWPTLVTTLTYGVQCFARYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNY</b>  <b>KTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNNSHKVYITADKQKNGI</b>  <b>KVNFKTRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSKLSKDPNEKRD</b>  <b>HMVLEFVTAAGITLGMDELYKEAAAREA<b>CCPGCC</b>ARA</b></p>
<p><b>Lyn<sup>xtc</sup>- Cerulean</b></p> <ul style="list-style-type: none"> <li>• Linker in gray</li> <li>• Cerulean in cyan</li> <li>• TC in orange</li> </ul>	<p>MGCIKSKGKDSLSDDGVDLKTQPVNRTERTIYVRDPTSNNKQQRPVPESQLLPQQR          FQTKDPEEQGDIVVALYPYDGIHPDDL SFKKGEKMKVLEEHGEWWKAKSLLTKK          EGFIPSNYVAKLNTLETEEWFVKDITR<b>CCAECCL</b>LAPGNSAGAF LIRESETLKGFSF          LSVRDFDPVHGDVIKHYKIRSLDNGGYYISPRITFPCISDMIKHYQKQADGLCRRL          KACISPKPQKPWDKDAWEIPRESIKLVKRLGAGQFGEVWMGYNNSTKVAVKTL          KPGTMSVQAFLEEANLMKTLQHDKLVRLYAVVTREPIYIITEYMAKGSLLDFLK          SDEGGKVLLPKLIDFSAQIAEGMAYIERKNYIHRDLRAANVLVSESLMCKIADFG          ARVIEDNEYTAREGAKFPIKWTAPEAINFGCFTIKSDVWSFGILLYEIVTYGKIYP          GRNADVMTALSQGYRMPRVENCPELDYDIMKMCWKEKAEERPTFDYLSVLD          DFYTATEGYQQQPGSGSGSDPPVAT<b>GSLVSKGEELFTGVVPILVELDGDVNGHK</b>  <b>FSVSGEGEGDATYGKLT LKFICTTGKLPVPWPTLVTTLTWGVQCFARYPDHMKQ</b>  <b>HDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNI</b>  <b>LGHKLEYNAISDNVYITADKQKNGIKANFKIRHNIEDGSVQLADHYQQNTPIGDGP</b>  <b>VLLPDNHYLSTQSKLSKDPNEKRDH MVLEFVTAAGITLGMDELYK</b></p>
<p><b>Lck<sup>xtc</sup>- Cerulean</b></p> <ul style="list-style-type: none"> <li>• Linker in gray</li> </ul>	<p>MGCGCSSHPEDDWMENIDVCENCHYPIVPLDGGKGTLLIRNGSEVRDPLVTYEGSN          PPASPLQDNLVIALHSYEP SHDGLGFEKGEQLRILEQSGEWWK AQSLLTTGQEGFI          PFNFVAKANSLEPEPWFFKNLSR<b>CCAECCL</b>LAPGNTHGSFLIRESESTAGSFLSVR          DFDQNQGEVVKHYKIRNLDNGGFYISPRITFPGLHELVRHYTNASDGLCTRLSRPC          QTQKPKPWWEDEWEVPRETLKLVRLGAGQFGEVWMGYNNGHTKVAVKSLK          QGSMSPDAFLAEANLMKQLQHQRLLVRLYAVVTQEPIYIITEYMENGLVDLTKTP</p>

• Cerulean in  
cyan  
TC in orange

SGIKLTINKLLDMAAQIAEGMAFIEERNYIHRDLRAANILVSDTLSCKIADFLARL  
IEDNEYTAREGAKFPIKWTAPEAINYGTFIKSDVWSFGILLTEIVTHGRIPYPGMT  
NPEVIQNLERGYRMVRPDNCPEELYQLMRLCWKERPEDRPTFDYLRSVLEDDFFTA  
TEGQYQPQPAGSGSGSDPPVATGSLVSKGEELFTGVVPILVELDGDVNGHKFSVS  
GEGEGDATYGKLTCLKFICTTGKLPVPWPTLVTTLTWGVQCFARYPDHMKQHDFD  
KSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGH  
KLEYNASDNVYITADKQKNGIKANFKIRHNIEDGSVQLADHYQQNTPIGDGPVLL  
PDNHYLSTQSKLSKDPNEKRDHMLLEFVTAAGITLGMDELYK

**Supplementary Table 2: results of the kinase inhibitor screen highlighting hits for c-Src closure**

Drug name	Z-scores for replicates			Mean	Standard Deviation	p value
	1	2	3			
<b>Vandetanib</b>	-1.014	-1.135	-1.031	-1.060	0.066	0.002
<b>CI-1040</b>	0.605	0.545	0.500	0.550	0.053	0.002
<b>VX745</b>	0.777	0.993	1.082	0.951	0.157	0.007
<b>CP-724714</b>	1.757	1.513	1.237	1.502	0.260	0.009
<b>PP2</b>	-1.056	-1.485	-1.186	-1.242	0.220	0.012
<b>CYC-116</b>	-3.074	-2.151	-2.397	-2.541	0.478	0.013
<b>Canertinib</b>	2.551	1.685	2.378	2.205	0.458	0.013
<b>Sorafenib</b>	0.890	0.515	0.765	0.723	0.191	0.017
<b>Regorafenib</b>	0.747	0.909	0.500	0.719	0.206	0.020
<b>Tozasertib</b>	-0.819	-0.667	-1.029	-0.838	0.182	0.020
<b>AC220</b>	0.608	1.040	1.134	0.927	0.281	0.023
<b>SMI-4a</b>	1.723	1.253	2.345	1.774	0.548	0.027
<b>SB203580</b>	1.216	0.946	0.593	0.918	0.313	0.029
<b>Barasertib</b>	0.645	0.978	0.490	0.704	0.250	0.030
<b>Ridaforolimus</b>	2.317	1.277	1.329	1.641	0.586	0.035
<b>PP1</b>	-1.744	-2.057	-1.049	-1.616	0.516	0.037
<b>Dianilinopyrimidine 0</b>	-0.968	-2.011	-1.958	-1.646	0.588	0.046
<b>Sunitinib</b>	0.176	0.245	0.559	0.327	0.204	0.066
<b>GSK2126458</b>	-0.507	-0.638	-1.082	-0.743	0.302	0.069
<b>E7080</b>	0.605	0.121	0.441	0.389	0.246	0.072
<b>PD173955-Analogue 1</b>	0.616	1.141	0.350	0.702	0.403	0.073
<b>Pazopanib</b>	-0.946	-1.277	-0.464	-0.895	0.409	0.080
<b>KU-60019</b>	0.304	1.017	0.464	0.595	0.374	0.082
<b>SU-6668</b>	0.101	0.638	0.670	0.470	0.320	0.088
<b>GSK-25</b>	0.534	1.909	0.882	1.108	0.715	0.098
<b>AG-490</b>	0.101	0.875	0.851	0.609	0.440	0.105
<b>Vatalanib</b>	0.203	1.440	1.189	0.944	0.654	0.108
<b>Masatinib</b>	1.554	0.598	0.420	0.857	0.610	0.111
<b>Saracatinib</b>	-1.284	-2.364	-0.696	-1.448	0.846	0.112
<b>Enzastaurin</b>	0.792	0.190	1.329	0.770	0.570	0.115
<b>JNJ38877605</b>	0.747	0.152	1.206	0.702	0.529	0.117
<b>SD169</b>	0.304	0.496	1.392	0.731	0.580	0.128
<b>Ruxolitinib</b>	0.463	0.182	1.147	0.597	0.496	0.132
<b>Danuserib</b>	-1.486	-0.449	-2.345	-1.427	0.949	0.139
<b>Axitinib</b>	0.980	0.426	0.077	0.494	0.455	0.148
<b>JNJ7706621</b>	0.147	0.625	0.070	0.281	0.301	0.153
<b>AMG-Tie2-1</b>	-3.203	-1.152	-0.706	-1.687	1.332	0.177
<b>Imatinib mesylate</b>	0.439	0.591	-0.103	0.309	0.365	0.184

<b>BMS 794833</b>	-0.117	1.304	0.839	0.675	0.725	0.201
<b>Tofacitinib</b>	-0.264	-0.652	-1.678	-0.865	0.731	0.216
<b>Foretinib</b>	-1.701	0.054	-1.888	-1.178	1.072	0.227
<b>AEE788</b>	-0.405	-1.584	-0.335	-0.775	0.702	0.243
<b>Dasatinib</b>	-0.178	-2.152	-0.824	-1.051	1.006	0.247
<b>Motesanib</b>	0.890	0.939	-0.265	0.521	0.681	0.249
<b>BX795</b>	0.961	1.455	-0.529	0.629	1.033	0.340
<b>PD153035</b>	-1.173	-0.652	0.140	-0.562	0.661	0.360
<b>Selumetinib</b>	-2.111	0.190	-0.629	-0.850	1.167	0.387
<b>PLX4720</b>	-0.203	-0.071	-1.057	-0.443	0.535	0.396
<b>Pelitinib</b>	-1.032	0.030	-0.324	-0.442	0.541	0.402
<b>PF-2341066</b>	0.036	-0.212	0.971	0.265	0.624	0.405
<b>Nilotinib</b>	1.655	0.024	-0.206	0.491	1.015	0.412
<b>RAF265</b>	1.085	-0.217	0.000	0.289	0.698	0.424
<b>PIK-294</b>	-0.440	0.408	0.420	0.129	0.493	0.486
<b>NVP-TAE684</b>	0.088	0.000	-2.853	-0.922	1.673	0.490
<b>AT-7519</b>	-0.320	-2.818	0.382	-0.919	1.682	0.494
<b>BI-2536(R-)</b>	-0.101	-0.213	0.361	0.016	0.304	0.544
<b>Cediranib</b>	-0.557	0.054	-0.210	-0.238	0.307	0.552
<b>ENMD-2076</b>	-0.264	0.082	-0.490	-0.224	0.288	0.570
<b>R406</b>	-1.993	-0.364	0.618	-0.580	1.319	0.602
<b>Erlotinib</b>	-1.182	0.189	-0.077	-0.357	0.727	0.619
<b>Bosutinib</b>	-0.821	-0.978	0.629	-0.390	0.886	0.641
<b>Selaciclib</b>	0.107	-0.121	-0.206	-0.073	0.162	0.721
<b>Tandutinib</b>	-0.528	-0.598	0.420	-0.235	0.568	0.743
<b>SB202190</b>	-0.176	-0.408	0.559	-0.008	0.505	0.756
<b>Linifanib</b>	0.783	0.909	-3.206	-0.505	2.340	0.799
<b>Afatinib</b>	-0.391	0.273	-0.412	-0.177	0.389	0.800
<b>Quercetin</b>	-0.890	-0.030	1.000	0.027	0.946	0.823
<b>SNS-032</b>	-0.642	0.284	0.103	-0.085	0.491	0.933
<b>PF-562271</b>	-0.178	0.636	-0.706	-0.082	0.676	0.947
<b>SU-5402</b>	-0.285	-0.455	0.353	-0.129	0.426	0.952
<b>CHIR-99021</b>	0.147	1.630	-2.028	-0.084	1.840	0.981
<b>Gefitinib</b>	0.712	-1.758	0.706	-0.113	1.424	0.999